SCHEMBL25427202

SCHEMBL25427202

Cc1cc(-c2cn[nH]c2)c2ccc(Cl)c(Cl)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BDKRB2 P30411 4/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PIM3 Q86V86 1/20 0.35
▸ PIM2 Q9P1W9 1/20 0.35
▸ ROCK2 O75116 4/20 0.35
▸ ROCK1 Q13464 4/20 0.35
▸ GPR35 Q9HC97 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ ATR Q13535 1/20 0.34
▸ ATRIP Q8WXE1 1/20 0.34
▸ PIK3R2 O00459 1/20 0.34
▸ MAT2A P31153 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ INCENP Q9NQS7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25425205 0.86 AURKA (0.35) LRRK2MAPTROCK2ROCK1AURKA
SCHEMBL27000337 0.78 ATR (0.38) ROCK2ROCK1ATRATRIPPIK3R2
SCHEMBL25423156 0.77 AKT1 (0.39) ROCK2ROCK1CHEK1
SCHEMBL26998196 0.77 MAP3K14 (0.38) LRRK2PIM1PIM2ROCK2ROCK1
SCHEMBL26999118 0.77 PTPN11 (0.40) PIM1PIM2ROCK2ROCK1CHEK1
SCHEMBL25424986 0.76 AKT2 (0.39) MAPTPIM1PIM3PIM2MET
SCHEMBL29039243 0.75 ROCK2 (0.38) ROCK2ROCK1
SCHEMBL26998140 0.75 ROCK2 (0.37) LRRK2ROCK2ROCK1
SCHEMBL25424805 0.75 ROCK2 (0.40) ROCK2ROCK1
SCHEMBL26998207 0.75 MAP3K14 (0.37) PIM1PIM2ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042737-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS INC (US) 2026-02-12 — — US disclosed
US-12281078-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2025-04-22 — — US disclosed
US-20250115579-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-04-10 — — US disclosed
EP-4486734-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS Immunesensor Therapeutics, Inc. (US) 2025-01-08 — — EP disclosed
CN-119137112-A Quinoline cGAS antagonist compounds 免疫传感器治疗股份有限公司 2024-12-13 — — CN disclosed
US-12134609-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-11-05 — — US disclosed
US-12091387-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-03-21 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20240002346-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-01-04 — — US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 — — US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 — — US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 — — US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 — — WO disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 — — WO disclosed
EP-4208452-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS Immunesensor Therapeutics, Inc. (US) 2023-07-12 — — EP disclosed
CN-116234802-A Quinoline CGAS antagonist compounds 免疫传感器治疗股份有限公司 2023-06-06 — — CN disclosed
US-20230081291-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
WO-2022051634-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2022-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002346-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-20250115579-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-12091387-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-20260042737-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, SSB, NT5C2 BDKRB2 1289/4885LRRK2 707/4885MAPT 4745/4885
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-12134609-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-12281078-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885
US-20230081291-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS BDKRB2 222/4885LRRK2 305/4885MAPT 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback